---
schema_version: "secwatch.filing_event.v1"
accession: "0000805928-24-000005"
form_type: "8-K"
ticker: "AXGN"
cik: "0000805928"
company_name: "Axogen, Inc."
filed_at: "2024-01-04T23:59:59+00:00"
generated_at: "2026-06-07T04:23:53.346060+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Axogen reports preliminary Q4 revenue $42.7M (+18% YoY); CEO Karen Zaderej to retire by Jan 2025

## Summary
- Q4 revenue $42.7M (+18% YoY); FY2023 revenue $158.8M (+15% YoY) at high end of $154-159M guidance.
- Gross margin for FY2023 expected ~80%; 375 Core Accounts (+13% YoY); 116 direct sales reps.
- CEO Karen Zaderej to retire by Jan 2025; Board will search for successor; she will consult for 9 months after transition.
- BLA submission for Avance Nerve Graft on track for H1 2024; Axoguard HA+ and Avive+ product rollouts planned.
- Avance Nerve Graft surpassed 100,000 implants since launch; strong commercial execution cited.

## SEC filing metadata
- accession: 0000805928-24-000005
- form_type: 8-K
- ticker: AXGN
- cik: 0000805928
- company_name: Axogen, Inc.
- filed_at: 2024-01-04T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/805928/000080592824000005/0000805928-24-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/805928/000080592824000005/axgn-20240104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000805928-24-000005
- JSON: https://secwatch.observer/filing/0000805928-24-000005.json
- Plain text: https://secwatch.observer/filing/0000805928-24-000005.txt

## Key facts
- Earnings Releases
  Axogen, Inc. reported full year 2023 results: revenue $158.8 million. Guidance reaffirmed.
  - Period: full year 2023
  - Revenue: $158.8 million
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: Full-year 2023 revenue is expected to be approximately $158.8 million, which represents a 15% increase over the full-year of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/805928/000080592824000005/0000805928-24-000005-index.htm
- Earnings Releases
  Axogen, Inc. reported fourth quarter 2023 results: revenue $42.7 million.
  - Period: fourth quarter 2023
  - Revenue: $42.7 million
  - Result: preliminary results
  source text: Fourth quarter revenue is expected to be approximately $42.7 million, which represents an 18% increase over the fourth-quarter of 2022 driven by solid performance across the product portfolio.
  evidence_url: https://www.sec.gov/Archives/edgar/data/805928/000080592824000005/0000805928-24-000005-index.htm
- Executive change
  Karen Zaderej departed as Chief Executive Officer and President at Axogen, Inc..
  - Action: retire
  - Role: Chief Executive Officer and President
  source text: Retirement of Karen Zaderej Karen Zaderej, the Chief Executive Officer (the “CEO”) and President of the Company informed the Company of her intention to retire in January 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/805928/000080592824000005/0000805928-24-000005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.